Fact-checked by Grok 2 weeks ago

Recombinant DNA

Recombinant DNA is a laboratory-constructed DNA molecule formed by the joining of genetic material from two or more distinct sources, typically involving the insertion of a specific DNA fragment into a vector like a plasmid for replication and expression in a host cell.^[1] This technology, pioneered in the early 1970s, allows for the isolation, amplification, and manipulation of individual genes, enabling precise control over genetic sequences outside their natural context.^[2] The foundational experiments were conducted by biochemists Paul Berg, who in 1972 created the first recombinant DNA by linking SV40 viral DNA to lambda phage DNA, though it was not propagated in cells, and Stanley Cohen and Herbert Boyer, who in 1973 successfully inserted recombinant DNA into Escherichia coli bacteria, demonstrating stable replication and gene expression.^[3]^[4] These advances built on the discovery of restriction enzymes, which act as molecular scissors to cut DNA at specific sites, and DNA ligases, which seal the joined fragments.^[5] Recombinant DNA technology sparked immediate biosafety concerns, with fears that novel gene combinations could produce pathogenic organisms or uncontrollably spread in the environment, prompting scientists to convene the 1975 Asilomar Conference on Recombinant DNA Molecules.^[6] At Asilomar, participants, led by Paul Berg and others, recommended voluntary moratoriums on certain experiments and established containment guidelines based on risk assessments, influencing national regulations like the NIH Guidelines for Recombinant DNA Research.^[7]^[8] Among its most significant achievements, the technology enabled the commercial production of human insulin in bacteria by Genentech in 1978, marking the first recombinant pharmaceutical and launching the biotechnology industry.^[9] It has since facilitated gene cloning for studying protein functions, development of genetically modified organisms for agriculture, and therapeutic applications including monoclonal antibodies and gene therapies.^[10] Despite early controversies, empirical evidence has shown recombinant organisms to be containable under proper protocols, with no verified instances of laboratory escapes causing harm.^[6]

Fundamentals

Definition and Core Principles

Recombinant DNA (rDNA) consists of DNA molecules artificially assembled in vitro by combining genetic segments derived from different organisms, synthetic oligonucleotides, or both, yielding chimeric sequences absent in any natural genome.^[11]^[2] This laboratory construction enables the propagation of non-native genes within host cells, leveraging universal DNA replication machinery.^[12] In contrast to natural recombination processes—such as meiotic crossing over or bacterial conjugation, which shuffle alleles within or across closely related genomes—rDNA formation involves deliberate cross-species or de novo synthesis, unbound by evolutionary constraints.^[13]^[14] Natural events preserve organismal compatibility, whereas rDNA disregards phylogenetic barriers, facilitating novel genetic architectures./Unit_II:_Replication_Maintenance_and_Alteration_of_the_Genetic_Material/8:_Recombination_of_DNA/8.01:_Types_and_Examples_of_Recombination) The core principles hinge on the specificity of Watson-Crick base pairing, where adenine-thymine and guanine-cytosine bonds dictate the fidelity of DNA strand annealing and ligation, ensuring stable integration and replication of foreign sequences. This predictability allows for the rational design of functional genetic elements, distinguishing rDNA from stochastic mutations or hybridizations. Unlike CRISPR-based editing, which deploys rDNA-derived guides for precise in-genome incisions and repairs, rDNA prioritizes extracellular assembly of entire cassettes over endogenous modification.^[12]

Molecular Mechanisms Enabling Recombination

The stable integration and propagation of ligated recombinant DNA constructs in host cells depend on endogenous replication and repair machinery, which resolves structural intermediates formed during in vitro assembly. DNA helicases, such as those in the RecBCD complex in bacteria, initiate recombination by unwinding double-stranded DNA and processing ends to generate single-stranded tails competent for strand invasion.^[15] These tails facilitate homologous pairing, enabling the exchange of genetic material with high specificity.^[16] DNA polymerases contribute to recombination by performing repair synthesis following strand invasion, extending nascent strands using the recombinant template to restore continuity. In eukaryotic systems, polymerases δ and ε, along with accessory factors, execute this extension during homologous recombination repair of double-strand breaks, ensuring accurate copying of the inserted sequence.^[17] Repair pathways, including non-homologous end joining and homologous recombination, ligate processed ends or exchange segments, with the latter providing template-directed fidelity to minimize errors.^[15] Empirical studies in vitro and in vivo, such as yeast mating-type switching and bacterial transformation assays, report recombination success rates exceeding 90% under conditions of sufficient homology and low damage, attributable to proofreading exonucleases and mismatch repair integration.00580-5)^[18] Epigenetic modifications modulate the accessibility of recombinant loci post-integration, influencing whether recombined genes achieve functional expression. Promoter regions in recombinant constructs recruit transcription factors, but chromatin remodeling complexes, such as SWI/SNF, reposition nucleosomes to expose DNA for polymerase access.^[19] DNA methylation at CpG sites within or near promoters can silence expression by recruiting repressive complexes, while histone acetylation promotes open chromatin states conducive to transcription initiation. In mammalian cell lines used for recombinant production, position variegation effects demonstrate how heterochromatin spreading reduces expression fidelity, with small-molecule inhibitors of histone deacetylases restoring activity in over 80% of silenced clones.^[20] These mechanisms underscore the causal link between epigenetic landscapes and the phenotypic output of recombined DNA.

Production Techniques

Restriction Enzymes, Ligation, and Assembly

Type II restriction endonucleases, the primary tools for precise DNA cleavage in recombinant DNA construction, recognize specific palindromic nucleotide sequences typically 4-8 base pairs long and hydrolyze phosphodiester bonds within or adjacent to these sites in the presence of Mg²⁺ ions.^[21] These enzymes function as homodimers, with each subunit binding to one half of the symmetric recognition sequence, enabling sequence-specific double-stranded breaks that generate either blunt or cohesive (sticky) ends essential for subsequent fragment joining.^[21] The first such enzyme, HindII, was isolated by Hamilton O. Smith from Haemophilus influenzae in 1970, marking the advent of tools for targeted DNA manipulation without reliance on non-specific shearing.^[22] A prototypical example is EcoRI, which cleaves at the palindromic site 5'-GAATTC-3', producing 5'-overhanging sticky ends of four nucleotides that facilitate directional ligation when compatible.^[23] DNA ligation follows restriction digestion to covalently join DNA fragments, with ATP-dependent ligases catalyzing the formation of phosphodiester bonds at nicks between a 5'-phosphate and adjacent 3'-hydroxyl group.^[24] The mechanism proceeds in three steps: the enzyme reacts with ATP to form a ligase-AMP intermediate linked by a phosphoamide bond, AMP transfers to the 5'-phosphate of the DNA nick forming a pyrophosphate linkage, and nucleophilic attack by the 3'-OH displaces AMP while sealing the backbone.^[25] Bacteriophage T4 DNA ligase, widely used in protocols due to its efficiency with cohesive and blunt ends, consumes one ATP molecule per bond formed and requires Mg²⁺ for activity, achieving ligation efficiencies often exceeding 90% under optimized conditions with equimolar fragment ratios.^[26] While traditional ligation relies on restriction-generated sticky ends for specificity, limitations such as incompatible sites or scar sequences prompted development of seamless assembly methods. Gibson assembly, introduced by Daniel G. Gibson and colleagues in 2009, enables scarless, isothermal joining of multiple DNA fragments (up to several hundred kilobases) through 20-40 bp homologous overlaps, employing a master mix of T5 exonuclease for 5' resection, Phusion polymerase for gap filling, and Taq ligase for nick sealing in a single 50°C reaction typically lasting 15-60 minutes.^[27] This one-pot protocol bypasses restriction-ligation cycles, reducing errors from restriction scars and enabling efficient multi-fragment assembly with success rates of 70-90% for 2-5 fragments when overlaps are designed with GC content matching the assembly temperature.^[28] Compared to sticky-end methods, Gibson improves versatility for complex constructs but requires precise overlap design to minimize off-target annealing.^[27]

Vectors, Host Systems, and Cloning Strategies

Plasmid vectors, such as pBR322 developed in 1977 by Bolivar and colleagues, serve as foundational tools for recombinant DNA propagation, featuring an origin of replication (ori) derived from ColE1 for autonomous replication in Escherichia coli and multiple cloning sites flanked by unique restriction enzyme recognition sequences.^[29] These vectors incorporate selectable markers, typically genes conferring resistance to antibiotics like ampicillin (bla) and tetracycline (tet), enabling identification of transformed cells through growth on selective media.^[30] Viral vectors, including adenoviruses and adeno-associated viruses, complement plasmids by facilitating gene delivery into eukaryotic cells, though they are less common for routine bacterial cloning due to higher complexity and immunogenicity risks.^[31] Host systems for recombinant DNA cloning prioritize E. coli strains like DH5α for their high transformation efficiency, often exceeding 10^8 to 10^9 transformants per microgram of DNA, rapid growth, and well-characterized genetics, making them ideal for initial propagation of prokaryotic-compatible inserts.^[32] Yeast hosts, such as Saccharomyces cerevisiae, support eukaryotic expression via episomal plasmids like YEp vectors, offering advantages in post-translational modifications absent in bacteria. Mammalian hosts like Chinese hamster ovary (CHO) cells are selected for complex protein production, accommodating up to 70% of approved recombinant biopharmaceuticals due to their capacity for human-like glycosylation and scalability in suspension culture.^[33] Transformation into hosts occurs via methods including electroporation, which applies electric pulses to induce transient membrane pores for DNA uptake, achieving efficiencies up to 10^10 transformants/μg in optimized E. coli protocols, or bacterial conjugation for plasmid transfer between strains using helper plasmids.^[34] Cloning strategies employ shuttle vectors, which contain dual origins of replication (e.g., bacterial ColE1 and yeast ARS) for propagation across kingdoms, facilitating insert transfer from E. coli to eukaryotic systems while minimizing sequence alterations. Empirical data indicate insert stability in such vectors persists over at least 100 generations without selection in compatible hosts, though repetitive or toxic sequences may necessitate low-temperature culturing at 30°C to reduce rearrangements.^[35]^[36]

Expression and Purification Methods

Recombinant protein expression in host organisms such as Escherichia coli commonly employs inducible promoters to regulate transcription of inserted genes. The T7 promoter system, utilizing T7 RNA polymerase expressed from an integrated prophage in strains like BL21(DE3), drives high-yield transcription upon induction with isopropyl β-D-1-thiogalactopyranoside (IPTG).^[37] This bacteriophage-derived mechanism enables rapid, robust expression levels often exceeding those of native promoters, with over 220,000 studies documenting its efficacy by 2021.^[38] Similarly, the lac promoter, regulated by the lac repressor and inducible by IPTG, allows controlled expression to mitigate toxicity from overexpressed proteins, facilitating tunable yields in bacterial hosts. Regulatory elements including ribosome binding sites and terminators further optimize translation initiation and mRNA stability, while codon optimization enhances compatibility with host tRNA pools. By substituting rare codons with synonymous, high-frequency alternatives specific to the expression organism—such as E. coli's preference for AT-rich codons—protein yields can increase by factors of 10 to 100-fold without altering the amino acid sequence.^[39] This strategy addresses translational bottlenecks, particularly for eukaryotic genes in prokaryotic systems, and has become standard for scalability in biomanufacturing.^[40] Purification of expressed proteins frequently incorporates affinity tags fused to the target polypeptide. The polyhistidine (His-tag), a sequence of 6-10 histidine residues developed in 1987, binds divalent metal ions like Ni²⁺ under immobilized metal affinity chromatography (IMAC), enabling one-step capture from crude lysates with recoveries often above 80%.^[41] Polishing steps via ion-exchange, hydrophobic interaction, or size-exclusion chromatography then achieve purities exceeding 90%, as demonstrated in preparative protocols preserving functional activity.^[42] At industrial scales, multi-column processes integrate these techniques to yield >95% purity, supporting gram-to-kilogram production for therapeutics while minimizing contaminants like host cell proteins.^[43] Advances in the 2020s include cell-free systems, which decouple expression from intact cells by using lysates enriched in transcription-translation machinery. These platforms, such as wheat germ or E. coli-based extracts, enable rapid synthesis without cellular metabolism, reducing endotoxin contamination risks inherent to live bacterial cultures and simplifying downstream purification.^[44] Yields have improved through energy regeneration modules and optimized feeds, approaching cell-based efficiencies for prototyping and small-scale production, with inherent biosafety advantages from absent viable cells.^[45]

Properties of Recombinant Organisms

Genetic Stability and Expression Dynamics

In optimized bacterial hosts like Escherichia coli strains engineered for reduced mutagenesis, recombinant DNA exhibits high genetic stability, with spontaneous mutation rates for cloned genes approximating 10^{-7} per gene per generation, enabling reliable propagation over extended culture periods. Long-term cultivation studies confirm that integrated recombinant constructs maintain fidelity across hundreds of generations under selective conditions, minimizing deletions or rearrangements through host strains deficient in homologous recombination pathways, such as recA mutants, which suppress unintended crossover events.^[46] While plasmid-based systems can suffer segregation loss without continuous selection, chromosomal integration or stabilized vectors yield mutation frequencies below 10^{-6} per generation, as validated by serial passaging experiments tracking sequence integrity via sequencing.^[47] Expression dynamics of recombinant genes are influenced by chromatin context in eukaryotic hosts, where position effects from nearby heterochromatin can induce variegated silencing, reducing transcript levels by up to 90% in susceptible integrations.^[48] This silencing spreads via histone modifications like H3K9 methylation, but can be mitigated by flanking elements such as chromatin insulators (e.g., the chicken β-globin HS4 sequence), which block enhancer-promoter interference and stabilize expression in 70-80% of transgenic lines.^[49] Quantitative PCR assays routinely quantify transgene copy number and correlate it with mRNA abundance, revealing consistent expression in insulated constructs over 50+ generations, though dynamic fluctuations occur due to epigenetic drift in mammalian cells.^[50] Compared to native genes, recombinant constructs often achieve 10- to 100-fold higher protein yields through potent heterologous promoters (e.g., CMV in mammalian systems), but may provoke greater immunogenicity in therapeutics owing to non-native glycosylation patterns or aggregation propensities absent in endogenous production.^[51] For instance, bacterially expressed recombinant proteins lack eukaryotic post-translational modifications, eliciting immune responses in clinical trials at rates 2-5 times higher than mammalian-derived counterparts, as observed in vaccine antigens like SARS-CoV-2 RBD.^[52] These differences underscore the need for host-specific optimization to balance yield with functional mimicry of native proteins.

Biosafety Profiles and Risk Assessments

Biosafety protocols for recombinant DNA research were formalized following the 1975 Asilomar Conference, which recommended risk-based containment measures to mitigate potential hazards from novel biotypes.^[53] These principles informed the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, establishing four biosafety levels (BL1 through BL4) calibrated to the agent's pathogenicity, host range, and environmental stability.^[54] BL1 applies to low-risk agents with no or low individual/community risk, featuring standard microbiological practices; BL2 adds restricted access and biohazard signage for moderate-risk agents; BL3 incorporates directional airflow and respiratory protection for indigenous/exotic agents with aerosol transmission potential; and BL4 employs full-body suits in Class III cabinets for high-risk agents posing severe threats without effective treatments.^[54] Containment escalates with recombinant experiments involving risk group 3 or 4 pathogens, requiring physical barriers and validated inactivation procedures to prevent dissemination.^[54] Empirical records indicate no verified instances of ecological releases causing harm from recombinant DNA lab accidents over decades of research. Reviews of global laboratory incidents from 1975 to 2021 document hundreds of exposures or infections, primarily involving select agents like anthrax or Ebola, but none attribute sustained environmental propagation or biodiversity impacts to recombinant constructs.^[55] A 1982 incident at Biogen involved spillage of engineered E. coli into a sewer, yet monitoring confirmed containment without detectable spread or virulence enhancement in wild populations.^[56] Pathogenicity assessments of recombinant strains consistently demonstrate that engineered organisms rarely surpass parental virulence under controlled conditions, with most hybrids exhibiting equivalent or attenuated effects absent deliberate enhancements. Studies on viruses like porcine reproductive and respiratory syndrome virus (PRRSV) and African swine fever virus (ASFV) show recombinant variants maintaining backbone pathogenicity or reduced lethality, as deletions in virulence genes (e.g., ASFV I177L) yield 50-100% survival rates in challenged animals compared to parental strains.^[57] Similarly, avian infectious bronchitis virus recombinants display molecular profiles aligning with attenuated parental lines, limiting hypervirulence risks.^[58] Regulatory evaluations by the U.S. Environmental Protection Agency (EPA) and Food and Drug Administration (FDA) affirm GMO safety through case-by-case reviews, with over 30 years of post-market surveillance since the 1990s revealing no causal links to health or ecological disruptions from approved recombinant crops and microbes.^[59] The National Academies of Sciences, Engineering, and Medicine's 2016 analysis of genetically engineered crops found no differences in toxicity or allergenicity versus conventional counterparts, supporting approvals under frameworks like the Coordinated Framework for Regulation of Biotechnology.^[60] Unintended dissemination is further constrained by quantitative declines in transformation efficiency beyond laboratory optimization, where natural uptake frequencies in bacteria range from 10^{-6} to 10^{-9} transformants per cell—orders of magnitude below electroporation yields of 10^{10} per microgram DNA—due to absent competence induction and DNA degradation in extracellular milieus.^[61] This exponential drop, compounded by host-vector incompatibilities, curtails horizontal gene transfer in non-sterile environments.^[62]

Applications

Therapeutic Proteins and Hormones

Recombinant human insulin, the first therapeutic protein produced using recombinant DNA technology, was developed by Genentech scientists who successfully expressed the insulin gene in Escherichia coli in 1978, leading to FDA approval of Humulin in October 1982.^[63]^[64] This advance supplanted animal-sourced insulins, which carried impurities triggering allergic reactions in up to 10-20% of patients, whereas recombinant versions demonstrated superior purity and equivalent glycemic control with markedly lower hypersensitivity rates in clinical evaluations.^[65]^[66] By enabling scalable microbial fermentation, it has sustained global diabetes management, with recombinant formulations comprising the majority of the insulin market valued at over $28 billion in 2023.^[67]^[68] Recombinant human growth hormone (somatropin), approved by the FDA in 1985 for treating growth hormone deficiency, eliminated the reliance on cadaveric pituitary extracts prone to contamination with prions causing iatrogenic Creutzfeldt-Jakob disease, as documented in cases from the 1980s National Hormone Pituitary Program.^[69]^[70] Long-term clinical data affirm its efficacy in restoring linear growth velocities comparable to untreated peers, with safety profiles unburdened by infectious risks inherent to human-derived material.^[71] Similarly, recombinant factor VIII concentrates, first approved in 1992, have transformed hemophilia A treatment by bypassing plasma donor pools that transmitted HIV to over 10,000 hemophiliacs worldwide in the 1980s, achieving viral safety through non-human production systems while maintaining hemostatic efficacy in prophylaxis and on-demand therapies.^[72]^[73] Monoclonal antibodies exemplify recombinant DNA's role in oncology, with trastuzumab (Herceptin), a humanized antibody targeting HER2, gaining FDA approval in 1998 for metastatic breast cancer.^[74] Pivotal trials reported median progression-free survival of 18.5 months with trastuzumab plus chemotherapy versus 6-7 months with chemotherapy alone, alongside overall survival gains of 4-5 months in HER2-positive cases.^[75]^[76] These outcomes have elevated five-year survival rates for early-stage HER2-positive breast cancer to over 90% in adjuvant settings, underscoring targeted precision over broad cytotoxics.^[77] Broader adoption of recombinant platforms has yielded market impacts exceeding tens of billions annually across these biologics, driven by reduced immunogenicity and consistent dosing.^[78]

Vaccines, Diagnostics, and Gene Therapies

Recombinant DNA technology facilitated the production of the first subunit vaccine for hepatitis B virus (HBV), Recombivax HB, approved by the U.S. Food and Drug Administration in 1986, which expresses the HBV surface antigen (HBsAg) in Saccharomyces cerevisiae yeast via insertion of the viral gene into a plasmid vector.^[79]^[80] This recombinant approach surpassed plasma-derived vaccines by avoiding risks of contamination with HIV or other pathogens present in human donor blood.^[81] Randomized clinical trials and post-licensure studies reported seroprotection rates of 90-95% in healthy adults and over 95% in infants after a three-dose series, contributing to the prevention of an estimated 310 million chronic HBV infections worldwide by 2020 through widespread immunization.^[82]^[83] In vaccine development, recombinant DNA techniques enabled the rapid cloning of pathogen genes, as seen in the 2020 mRNA-based COVID-19 vaccines from Pfizer-BioNTech and Moderna, where the SARS-CoV-2 spike protein coding sequence was inserted into bacterial plasmids for amplification and subsequent in vitro transcription into mRNA.^[84] These plasmids, produced through recombinant methods, ensured high-fidelity template generation, allowing host cells to synthesize the spike protein antigen upon vaccination. Phase 3 randomized controlled trials demonstrated 94-95% efficacy against symptomatic SARS-CoV-2 infection in initial variants, with over 90% reduction in severe disease across diverse populations.^[85] Such applications highlight recombinant DNA's role in scaling antigen design beyond traditional protein expression systems. For diagnostics, recombinant antigens like HIV-1 gp120, expressed in mammalian or insect cells via inserted viral envelope genes, form the basis of antibody-detection assays such as enzyme-linked immunosorbent assays (ELISAs).^[86] Second- and third-generation HIV tests incorporate these recombinant proteins alongside synthetic peptides to bind patient antibodies, achieving sensitivities above 99% and specificities of 98-99.9% while reducing false positives from whole-virus lysates.^[87]^[88] This shift, evident by the early 1990s, improved early detection windows and reliability in blood screening and clinical diagnostics. Gene therapies leverage recombinant DNA to engineer viral vectors, such as adeno-associated virus (AAV) serotype 9 in Zolgensma, approved by the FDA in 2019 for spinal muscular atrophy (SMA) in pediatric patients under 2 years. The therapy inserts a functional human SMN1 gene into the AAV genome, produced in HEK293 cells via triple-transfection with recombinant helper plasmids, enabling motor neuron expression of survival motor neuron protein.^[89]^[90] In the phase 3 STR1VE trial, all 22 treated symptomatic infants achieved event-free survival (no death or permanent ventilation) at 14 months, versus 26% in untreated historical controls, with 59% sitting independently for 30 seconds or more by 16-18 months—milestones unmet in natural history data.^[91]^[92] Long-term follow-up confirmed sustained motor gains, underscoring recombinant AAV's efficacy in monogenic disorders despite challenges like vector immunogenicity.

Agricultural Modifications and Crop Enhancements

Recombinant DNA technology has enabled the development of crops with targeted enhancements, primarily through the insertion of genes conferring pest resistance, herbicide tolerance, and nutritional improvements. These modifications, first commercialized in the mid-1990s, have been adopted on millions of hectares worldwide, with empirical data from field trials demonstrating increased yields and reduced input requirements. For instance, insect-resistant varieties incorporate the cry gene from Bacillus thuringiensis (Bt), producing proteins toxic to specific lepidopteran pests while harmless to non-target organisms. Herbicide-tolerant crops express enzymes like CP4 EPSPS, allowing post-emergence application of glyphosate without crop damage. Nutritional enhancements, such as in Golden Rice, introduce biosynthetic pathways for provitamin A. Long-term monitoring of these crops, spanning over two decades, has yielded no verified evidence of health impacts from consumption, as confirmed by post-market surveillance across billions of meals.^[93]^[94] Bt cotton, introduced commercially by Monsanto in 1996, exemplifies pest resistance enhancements. By expressing Bt toxins, it targets bollworms and other insects, leading to substantial reductions in insecticide applications. Global analyses indicate an average 37% decrease in pesticide use for Bt cotton adopters, with country-specific data showing 60-70% reductions in China and Argentina.^[95] In India, Bt cotton adoption since 2002 reduced bollworm-specific insecticide use from 71% of applications in 2001 to 3% by 2011, alongside yield increases of 20-30% in early years due to minimized crop damage. Field trials and farm-level studies further document improved economic returns and decreased environmental pesticide residues, countering concerns with data from controlled and observational assessments showing no unintended ecological disruptions beyond targeted pest control.^[96] Herbicide-tolerant soybeans, commercialized as Roundup Ready in 1996, facilitate simplified weed management and conservation tillage. The modification allows glyphosate application, enabling no-till practices that preserve soil structure and reduce erosion. Adoption has correlated with yield boosts of approximately 10% in U.S. soybean production, attributed to better weed control and flexible planting. No-till acreage expanded significantly post-introduction, enhancing carbon sequestration by maintaining soil organic matter; estimates suggest U.S. corn-soy rotations with herbicide-tolerant varieties act as a net carbon sink. Empirical tillage data from grower surveys confirm these shifts, with reduced fuel and labor inputs, while agronomic trials verify compositional equivalence to conventional soybeans.^[97]^[98] Golden Rice, developed in 2000 by inserting genes from daffodil and Erwinia bacterium to produce beta-carotene, targets vitamin A deficiency affecting millions in rice-dependent regions. Field evaluations demonstrated sufficient provitamin A levels to meet daily needs from modest consumption, with no impacts on yield or grain quality. The Philippines approved commercial propagation of Golden Rice event GR2E in July 2021, marking the first such authorization globally after extensive biosafety assessments. Multi-year trials in Asia confirmed nutritional efficacy and agronomic performance equivalent to non-modified rice, addressing unsubstantiated allergenicity claims through compositional analyses showing no novel proteins beyond the intended pathway.^[99]^[100]

Industrial Enzymes and Bioprocessing

Recombinant DNA technology facilitates the heterologous expression of enzyme genes in microbial hosts such as bacteria and fungi, enabling high-yield production of industrial enzymes that catalyze bioprocessing reactions in sectors like food manufacturing and biofuels. This approach circumvents limitations of native enzyme extraction, such as low yields and variable purity from animal or plant sources, resulting in scalable fermentation processes that lower operational costs by optimizing enzyme stability, activity, and dosage requirements.^[101] A landmark example is recombinant chymosin, the primary milk-coagulating enzyme in cheese production. The bovine chymosin gene was cloned and expressed in hosts like Escherichia coli and Aspergillus niger during the 1980s, with Pfizer achieving commercialization in 1990 following FDA approval as the first recombinant food enzyme. This replaced scarce, calf-derived rennet, which required slaughter of young animals, and reduced production costs through simplified downstream processing and higher yields, with fermented chymosin now comprising the majority of the market and projected to expand from USD 5.2 billion in 2025 at a 4.2% CAGR.^[102]^[103]^[104] In cellulosic biofuel production, recombinant cellulase cocktails have enhanced biomass saccharification into fermentable sugars for ethanol fermentation. Novozymes developed advanced formulations like the Cellic® CTec series starting in the mid-2000s, incorporating engineered endoglucanases, exoglucanases, and β-glucosidases expressed in filamentous fungi such as Trichoderma reesei. These achieved up to 1.9-fold improvements in glucose conversion efficiency over prior generations at target loadings, alongside broader industry-wide cellulase cost reductions of 20-fold since early recombinant efforts, thereby elevating ethanol titers and process economics.^[105]^[106] Overall, rDNA-derived industrial enzymes drive efficiency gains, with applications yielding 20-50% cost savings in targeted bioprocesses through minimized enzyme use and waste. The sector contributes to a global industrial enzymes market projected at USD 8.42 billion in 2025, growing at 7.3% CAGR, where recombinant innovations underpin high-performance variants for sustainable manufacturing.^[107]^[108]

Historical Development

Foundational Discoveries Pre-1970

In 1952, Alfred Hershey and Martha Chase conducted an experiment using bacteriophage T2 infecting Escherichia coli, labeling viral DNA with radioactive phosphorus-32 and protein coats with sulfur-35; after infection, agitation in a blender separated empty phage coats from bacteria, revealing that phosphorus radioactivity entered the cells and produced progeny phages, while sulfur remained outside, thereby confirming DNA as the hereditary material rather than protein.^[109] That same year, Norton Zinder and Joshua Lederberg discovered genetic transduction in Salmonella typhimurium, where bacteriophage P22 mediated the transfer of bacterial genes between strains, providing early evidence of phage-facilitated DNA exchange and foreshadowing mechanisms for introducing foreign genetic material into host cells.^[110] The elucidation of DNA's double-helix structure by James Watson and Francis Crick in 1953, published on April 25 in Nature, proposed a model with antiparallel polynucleotide chains twisted into a right-handed helix, base-paired via hydrogen bonds (adenine-thymine, guanine-cytosine), enabling semi-conservative replication and laying the physicochemical foundation for understanding how genetic information could be manipulated.^[111] This structural insight complemented prior biochemical evidence, such as Chargaff's rules on base equivalences, and shifted focus toward enzymatic tools for DNA handling. Host-controlled restriction of bacteriophages, first observed in the early 1950s by Salvador Luria and Giuseppe Bertani, indicated bacterial defenses that degraded foreign DNA while protecting host DNA via methylation; Werner Arber's work in the mid-1960s identified the enzymatic basis, isolating a modification enzyme in 1965 and demonstrating sequence-specific endonucleolytic cleavage, which prefigured precise DNA cutting essential for later recombination.^[112] Concurrently, DNA ligase was discovered in 1967 by independent groups: Martin Gellert identified an NAD+-dependent enzyme in E. coli extracts, while I. Robert Lehman, Charles C. Richardson, and Jerard Hurwitz described ATP-dependent ligases from T4 phage-infected cells, catalyzing the formation of phosphodiester bonds to join DNA strands with cohesive or blunt ends, thus enabling in vitro sealing of cut DNA.^[113] These enzymes collectively provided the biochemical toolkit—DNA as target, phages as vectors, restriction for incision, and ligation for closure—that underpinned subsequent recombinant DNA construction.

1970s Milestones and Regulatory Debates

In 1972, Paul Berg and colleagues at Stanford University constructed the first recombinant DNA molecules in vitro by covalently joining DNA from simian virus 40 (SV40) with lambda phage DNA, demonstrating the feasibility of splicing disparate genetic sequences using restriction enzymes and DNA ligase.^[114] This hybrid molecule, though not yet introduced into a host cell due to emerging biosafety concerns, marked the initial proof of concept for genetic recombination outside natural biological processes.^[115] Berg's work built on foundational enzyme discoveries but highlighted potential risks, such as unintended propagation of viral oncogenes in bacterial hosts like Escherichia coli.^[116] The following year, in 1973, Stanley Cohen at Stanford and Herbert Boyer at the University of California, San Francisco, advanced the technique by successfully transforming E. coli with recombinant plasmids, creating biologically functional replicons that incorporated foreign DNA, such as resistance genes from other bacteria.^[117] Their method involved cleaving plasmid pSC101 with restriction endonuclease EcoRI, ligating it with compatible fragments, and achieving stable propagation in E. coli via calcium chloride-mediated uptake, enabling the first in vivo expression of recombinant genes in a prokaryotic host.^[9] This experiment established plasmid vectors as practical tools for gene cloning, accelerating the field's momentum despite parallel concerns over ecological and pathological risks from engineered organisms.^[118] These breakthroughs prompted immediate debate on biosafety, culminating in the 1975 Asilomar Conference organized by Berg and others, where over 140 scientists recommended a voluntary moratorium on certain recombinant experiments involving tumor viruses or antibiotic resistance genes to assess hazards.^[6] The conference emphasized physical containment (e.g., P1-P4 labs) and biological safeguards, influencing the National Institutes of Health (NIH) to issue formal guidelines in 1976 that classified experiments by risk levels without prohibiting research outright.^[119] This self-imposed framework, rooted in empirical risk evaluation rather than preemptive bans, preserved scientific autonomy and averted more restrictive federal legislation, allowing cautious progress.^[120] By 1977, amid these evolving guidelines, Genentech demonstrated practical application by inserting a synthetic human insulin gene into E. coli, achieving the first microbial production of a human protein and validating recombinant DNA's therapeutic potential under controlled conditions.^[121] This milestone, involving chemical synthesis of the A and B insulin chains followed by plasmid-based expression, underscored how regulatory caution enabled innovation without halting foundational work.^[122]

Commercial Expansion 1980s-2000s

The U.S. Supreme Court's decision in Diamond v. Chakrabarty on June 16, 1980, established that man-made microorganisms, including those modified via recombinant DNA techniques, were patentable as non-naturally occurring compositions of matter, thereby facilitating intellectual property protections essential for commercial investment in biotechnology.^[123]^[124] This ruling overcame prior Patent Office rejections and spurred the formation of venture-backed firms focused on scaling recombinant DNA applications from laboratory prototypes to industrial production. In 1982, the FDA approved Humulin, the first recombinant human insulin produced by Eli Lilly using E. coli bacteria engineered with synthetic insulin genes licensed from Genentech, marking the inaugural commercial recombinant pharmaceutical and demonstrating scalable microbial fermentation for therapeutic proteins.^[64]^[125] This approval, completed in under six months, catalyzed a biotechnology investment surge, with firms like Genentech achieving the industry's first IPO in 1980 and Amgen following in 1983, collectively raising billions to expand recombinant production facilities. By the late 1980s, recombinant erythropoietin (EPO), marketed as Epogen by Amgen, received FDA approval on June 1, 1989, for treating anemia in chronic renal failure patients, generating over $37 billion in U.S. sales by 2012 and exemplifying the economic viability of recombinant biologics in addressing unmet medical needs.^[126]^[127] The 1990s saw recombinant DNA extend to agriculture, with the FDA deeming the Flavr Savr tomato—engineered by Calgene to suppress polygalacturonase for delayed ripening—safe for consumption in 1994, enabling its limited commercialization as the first genetically modified whole food crop.^[128]^[129] Concurrently, Monsanto and others commercialized Bt corn hybrids in 1996, incorporating Bacillus thuringiensis toxin genes to confer insect resistance, which rapidly achieved widespread adoption for yield protection without broad-spectrum pesticides.^[130]^[131] These milestones drove industry consolidation and global expansion, with U.S. biotech firms increasing their share of recombinant product pipelines through the decade, supported by strengthened patent frameworks and regulatory precedents affirming product safety based on compositional equivalence to conventional counterparts.^[132]

Advances 2010s-2025 Including CRISPR Integration

The development of CRISPR-Cas9 in 2012 marked a pivotal advance in recombinant DNA technology, enabling precise, programmable cleavage of target DNA sequences guided by a synthetic single-guide RNA (sgRNA) fused to the Cas9 endonuclease from Streptococcus pyogenes. This system, demonstrated in vitro by Jinek et al., facilitates homology-directed repair for the targeted insertion of recombinant DNA constructs, surpassing the limitations of earlier methods like restriction enzyme-based cloning or random integration via transposons or viral vectors.^[133] Subsequent adaptations, including those by Zhang's group for eukaryotic genome editing in 2013, integrated CRISPR into recombinant workflows for multiplexed modifications, accelerating applications in synthetic biology and precision therapeutics.^[134] In synthetic biology, recombinant DNA techniques converged with CRISPR for constructing minimal genomes and complex cellular systems. The 2016 creation of JCVI-syn3.0, a synthetic bacterial cell with a 531 kb genome encoding 473 genes, involved recursive assembly of chemically synthesized DNA fragments into yeast via recombination, followed by transplantation into recipient cells, yielding the smallest autonomously replicating genome known.^[135] This approach, building on prior Venter Institute work, highlighted rDNA's role in bottom-up cellular engineering, with CRISPR later enabling iterative refinements like gene knockouts to probe essentiality. Similarly, rDNA-engineered organoids—3D tissue models derived from stem cells with integrated transgenes—emerged in the 2010s for disease modeling, using CRISPR to insert reporters or modifiers for enhanced functionality in drug screening.^[136] Recombinant DNA underpinned mRNA vaccine platforms accelerated during the 2020 COVID-19 response, where plasmid vectors encoding the SARS-CoV-2 spike gene were used to produce in vitro transcribed mRNA, with over 13 billion doses administered globally by 2023 demonstrating scalable rDNA manufacturing.^[84] Gene therapies, leveraging rDNA-packaged vectors like AAV or lentiviruses edited via CRISPR, advanced with FDA approvals such as Luxturna (2017) for retinal dystrophy and multiple CAR-T products, driving market expansion to approximately $796 billion for rDNA technologies in 2024.^[137] Regulatory support included the FDA's RMAT designation under the 2017 21st Century Cures Act, expediting review for regenerative therapies showing preliminary efficacy, with over 140 designations by 2025 facilitating faster paths for CRISPR-integrated rDNA products addressing unmet needs in oncology and rare diseases.^[138]

Controversies and Debates

Biosafety and Environmental Risk Claims

Early proponents of recombinant DNA technology in the 1970s faced substantial biosafety concerns, including fears that engineered organisms could escape containment and evolve into uncontrollable pathogens, evoking "Andromeda Strain"-like scenarios of extraterrestrial or synthetic microbes devastating human populations.^[139] ^[140] These apprehensions, amplified by popular media and speculative "what if" arguments, led to a voluntary moratorium on certain experiments and the 1975 Asilomar Conference, where scientists established physical and biological containment guidelines to mitigate risks such as unintended gene dissemination.^[139] ^[119] Longitudinal evidence has largely refuted these catastrophic predictions: since the 1970s, hundreds of millions of recombinant DNA experiments have been performed globally under regulated conditions, with no documented cases of laboratory escapes causing verifiable environmental harm or public health crises attributable to the technology.^[139] ^[141] Institutional oversight, including NIH recombinant DNA guidelines implemented in 1976 and updated iteratively, has ensured compliance without evidence of systemic failures, as confirmed by retrospective analyses marking the technology's 50-year history.^[142] This track record underscores that hypothetical risks, while prompting prudent precautions, have not materialized into causal harms despite widespread lab adoption. In environmental contexts, particularly for genetically modified organisms (GMOs) derived from recombinant DNA, claims of unique ecological disruptions—such as persistent transgene persistence in non-target species or biodiversity loss—have been tested against decades of field monitoring data. The 2016 National Academy of Sciences, Engineering, and Medicine report, synthesizing over 1,000 studies, found no substantiated evidence that genetically engineered crops pose greater environmental risks than those from conventional breeding or sexual hybridization, including no differential impacts on non-target organisms or soil ecosystems. Allergenicity and toxicity assessments for approved GM varieties have consistently yielded negative results, with no verified increases in allergic responses linked to consumption.^[143] ^[144] A specific mechanism invoked in risk claims, horizontal gene transfer (HGT) of transgenes to wild relatives or microbes, occurs at demonstrably low frequencies in natural settings, typically below 10^{-9} transfers per recipient cell under optimal lab conditions and even rarer in field soils due to barriers like DNA degradation and host incompatibility.^[145] Empirical field trials spanning 20+ years show no instances of ecologically significant HGT from transgenic plants to bacteria or weeds leading to adaptive advantages or invasions, aligning with causal assessments that prioritize observed outcomes over unverified potentials.^[146] These findings counter early assertions by emphasizing data from controlled releases and surveillance, where transgene stability remains confined without amplifying natural variability.^[147]

Ethical Objections and "Playing God" Arguments

Critics of recombinant DNA technology in the 1970s invoked the "playing God" argument, contending that deliberate genetic recombination across species boundaries represented human hubris and an impermissible interference with natural or divine creation. Figures such as activist Jeremy Rifkin protested recombinant DNA research as an unethical overreach, equating it with moral transgression akin to mythological warnings against tampering with life's essence.^[148] ^[149] These objections drew on philosophical and religious grounds, positing that such manipulations disrupted inherent order and risked unintended existential consequences beyond empirical risks.^[150] Such absolutist critiques have been rebutted by the empirical successes of recombinant DNA applications, which demonstrate practical utility without substantiating claims of divine violation. Recombinant human insulin, the first such product approved by the U.S. Food and Drug Administration on October 29, 1982, revolutionized diabetes treatment by providing a purer, more abundant alternative to animal-derived insulin, benefiting millions without observable ethical fallout.^[151] ^[63] This outcome underscores a causal reality: targeted genetic engineering yields verifiable health gains, prioritizing human welfare over abstract prohibitions.^[152] Fears of "designer babies" and heritable alterations, often framed as ultimate hubris, remain overstated in the recombinant DNA context. The 2018 case of He Jiankui, who used CRISPR-Cas9—a tool building on recombinant principles—to edit human embryos for HIV resistance, stands as an isolated, widely condemned violation rather than an inevitable extension of the technology.^[153] ^[154] Germline editing's rarity and regulatory scrutiny highlight that recombinant DNA's core applications focus on non-heritable, therapeutic interventions, mitigating moral absolutism through evidence-based governance. Bioconservative perspectives, which prioritize preserving unaltered human nature against enhancement, contrast with pro-innovation views emphasizing adaptive progress.^[155] Yet, decades of recombinant DNA deployment reveal no systemic erosion of stewardship; instead, innovations like insulin production exemplify how genetic tools augment human capability, aligning causal mechanisms of disease mitigation with responsible dominion over biological challenges.^[65] This empirical track record favors utility-driven advancement over precautionary moralism, as unalloyed restraint would forgo proven lifespans extended by such technologies.

Intellectual Property, Access, and Economic Critiques

The U.S. Supreme Court's decision in Diamond v. Chakrabarty on June 16, 1980, ruled that genetically modified organisms, including living microorganisms engineered via recombinant DNA techniques, were eligible for patent protection as non-naturally occurring manufactures, thereby establishing a legal foundation for biotech intellectual property rights.^[123] This precedent facilitated the patenting of recombinant DNA inventions, enabling firms like Genentech—the first company dedicated to recombinant DNA technology, founded in 1976—to secure exclusive rights that recouped high-risk R&D investments in products such as synthetic human insulin approved in 1982.^[156] Empirical analyses indicate that such patents causally boosted cumulative innovation and private R&D expenditures in biotechnology by providing appropriable returns, with studies showing reduced innovation in regimes lacking strong IP enforcement.^[157] The global recombinant DNA technology market, propelled by these incentives, reached approximately $796 billion in 2024, reflecting sustained investment in scalable bioproducts.^[137] Critics, including advocacy groups and some economists, argue that biotech patents create monopolies leading to elevated prices, as seen in recombinant insulin where list prices rose over 500% from 2001 to 2015 amid extended patent protections and limited biosimilar entry.^[158] However, this overlooks the causal role of IP in funding the initial development of recombinant insulin, which replaced animal-derived versions and spurred iterative improvements; post-patent generic and biosimilar competition has driven U.S. insulin prices down by up to 70% for certain formulations since 2021, with evidence from patent expirations correlating to broader long-term price reductions via market entry.^[159] Economic models demonstrate that without patent incentives, R&D for complex biologics like those from recombinant DNA would decline sharply, as high fixed costs and low marginal reproduction costs deter investment absent exclusivity.^[160] Attributions of monopoly power often stem from sources critiquing pharmaceutical practices broadly, yet fail to account for biotech's demonstrated productivity gains, such as a 10-fold increase in novel drug approvals per R&D dollar invested since the 1980s IP expansions.^[161] On global access, recombinant DNA technologies have incorporated humanitarian licensing models to mitigate IP barriers in developing nations; for instance, Golden Rice—a beta-carotene-enriched variety developed via recombinant methods to combat vitamin A deficiency affecting 250 million preschool children annually—features royalty-free sublicenses granted by the Golden Rice Humanitarian Board to public breeders in target countries, with patent holders like Syngenta and Monsanto waiving fees for non-commercial use in low-income regions.^[162]^[163] These arrangements, structured post-2000, have enabled tech transfer without royalties for subsistence farming, countering claims of inherent IP obstruction.^[164] Opposition to such access, frequently from non-governmental organizations, emphasizes ideological concerns over empirical barriers, as licensing data show over 70 patents managed collaboratively to facilitate deployment rather than block it.^[165] Causal evidence links these IP frameworks to accelerated innovation diffusion, with biotech patenting correlating to higher technology adoption rates in agriculture-dependent economies when paired with targeted waivers.^[166]

Empirical Validation of Benefits Over Hyped Risks

Recombinant DNA-derived therapeutics, including insulin, growth hormones, and monoclonal antibodies, have treated hundreds of millions of patients annually since the 1980s, with recombinant human insulin alone serving over 400 million diabetics worldwide as the primary treatment standard. These biologics have demonstrated superior efficacy and purity compared to animal-derived predecessors, reducing immunogenicity risks and enabling scalable production without reliance on scarce biological sources. In agriculture, meta-analyses of field trials show genetically modified crops adopting recombinant DNA techniques yield an average 22% increase over non-GM counterparts, alongside 37% pesticide reductions, benefiting smallholder farmers in adopting regions through higher incomes and lower input costs.^[167] The International Service for the Acquisition of Agri-biotech Applications reports sustained adoption across 29 countries, correlating with enhanced food security metrics absent in non-adopting areas. Risk-benefit assessments affirm favorable ratios, with no documented human health epidemics linked to recombinant DNA products despite billions of exposure instances over decades.^[168] Cochrane reviews of recombinant vaccines, such as those for hepatitis B and zoster, confirm safety profiles comparable to or better than traditional formulations, with rare adverse events outweighed by prevented disease burdens.^[169] Claims of GMO-induced superweeds trace to herbicide overuse in monocultures, a phenomenon predating and exceeding GM adoption in conventional systems, per weed science consensus.^[170] Media amplification of outlier studies, such as Pusztai's 1998 preliminary rat feeding trial on lectin-expressing potatoes—which the Royal Society critiqued for flawed controls, small sample sizes, and failure to isolate GM effects from the toxin itself—contrasts with systematic reviews encompassing over 1,700 peer-reviewed studies finding no credible evidence of toxicity or allergenicity in approved GM crops.^[171] The U.S. National Academies of Sciences, Engineering, and Medicine's 2016 consensus report, drawing from thousands of publications, concludes no differential risks from recombinant DNA methods versus conventional breeding, underscoring hype-driven narratives over empirical aggregates.^[168]^[172]

References

[1]
Isolating, Cloning, and Sequencing DNA - NCBI - NIH
DNA molecules produced by splicing together two or more DNA fragments are called recombinant DNA molecules; they have made possible many new types of cell ...
[2]
Recombinant DNA - The Cell - NCBI Bookshelf - NIH
Recombinant DNA technology, which provided scientists with the ability to isolate, sequence, and manipulate individual genes derived from any type of cell.
[3]
https://genome.gov/25520302/online-education-kit-1972-first-recombinant-dna
[4]
When was recombinant DNA technology invented? - Britannica
In 1973 American biochemists Stanley N. Cohen and Herbert W. Boyer became the first to insert recombined genes into bacterial cells, which then reproduced.
[5]
Recombinant DNA in the Lab | Smithsonian Institution
By the early 1970s, investigators had isolated several plasmids as well as special enzymes known as “restriction endonucleases” that work like scissors to cut ...
[6]
Asilomar and Recombinant DNA: The End of the Beginning - NCBI
The principal items on the agenda were possible revision of the definition of recombinant DNA molecules (unchanged since 1976) and the consideration of ...
[7]
Asilomar 1975: DNA modification secured - Nature
Sep 17, 2008 · At that gathering, the International Congress on Recombinant DNA Molecules, held at the Asilomar Conference Center in Pacific Grove, California, ...
[8]
[PDF] NIH Guidelines for Research Involving Recombinant or Synthetic ...
Definition of Recombinant and Synthetic Nucleic Acid ... 1) Recombinant nucleic acid molecules, or DNA or RNA derived from recombinant nucleic acid.
[9]
Herbert W. Boyer and Stanley N. Cohen | Science History Institute
By inventing recombinant-DNA technology, Boyer and Cohen jump-started the biotechnology industry, including Genentech, which creates important applications ...
[10]
Role of Recombinant DNA Technology to Improve Life - PMC
Recombinant DNA technology comprises altering genetic material outside an organism to obtain enhanced and desired characteristics in living organisms or as ...
[11]
Recombinant DNA | Summary - What is Biotechnology
The first protocol for creating recombinant DNA was put forward in the early 1970s by Peter Lobban and Armin Dale Kaiser at Stanford University Medical School.
[12]
Recombinant DNA Technology
Recombinant DNA technology involves using enzymes and various laboratory techniques to manipulate and isolate DNA segments of interest.Missing: core | Show results with:core
[13]
How is recombinant DNA technology different from genetic ... - Quizlet
The main difference between the two is that recombinant DNA technology is an artificial process, while genetic recombination during meiosis is a natural ...
[14]
Recombinant DNA technology – Steps, Methods & Examples - evitria
Dec 13, 2022 · Recombinant DNA differs from genetic recombination in that it results from artificial methods in the test tube, while the latter is a normal ...
[15]
Homologous recombination in DNA repair and DNA damage tolerance
Jan 1, 2008 · Homologous recombination (HR) comprises a series of interrelated pathways that function in the repair of DNA double-stranded breaks (DSBs) and interstrand ...
[16]
https://www.nature.com/scitable/topicpage/genetic-recombination-514
[17]
Managing DNA polymerases: Coordinating DNA replication ... - PNAS
In addition to their roles in chromosomal DNA replication, DNA polymerases participate in numerous DNA repair pathways, including double-strand break repair (61 ...
[18]
DNA mismatch repair efficiency and fidelity are elevated during DNA ...
MMR activity, as measured by both in vitro and in vivo approaches, increases during S phase to the highest extent within normally growing cells.
[19]
Small molecule epigenetic modulators for enhancing recombinant ...
Dec 27, 2021 · Small molecule epigenetic modulators are useful tools for regulating gene expression by inducing chromatin remodeling.
[20]
[PDF] Pharmaceutical - Open Access Journals
The main epigenetic processes that influence transgene expression patterns are trans- gene localization, cytosine methylation of the DNA, post-translational ...
[21]
Review Type II restriction endonucleases: structural, functional and ...
Type II restriction endonucleases are homodimeric enzymes that recognize a palindromic sequence of double-stranded DNA and, in the presence of Mg2+ ...
[22]
[PDF] Hamilton O. Smith - Nobel Lecture
We were confident that we had discovered a new and highly active restriction enzyme. Furthermore, it appeared to require only Mg2+ as a cofactor, suggesting ...
[23]
How restriction enzymes became the workhorses of molecular biology
When John Morrow and Paul Berg ( 26) discovered that SV40 DNA contained a single site for the restriction endonuclease EcoRI, which had been discovered in Herb ...
[24]
ATP-dependent DNA ligases - PMC - PubMed Central - NIH
The ATP-dependent DNA ligases catalyze the joining of single-stranded breaks (nicks) in the phosphodiester backbone of double-stranded DNA in a three-step ...
[25]
Dynamics of phosphodiester synthesis by DNA ligase - PNAS
1a): (i) ligase reacts with ATP (or NAD+) to form a covalent ligase–adenylate intermediate, in which AMP is linked via a phosphoamide (P–N) bond to Nζ of a ...
[26]
T4 DNA ligase structure reveals a prototypical ATP-dependent ...
Aug 29, 2018 · All classic DNA/RNA ligases join a 5′-phosphorylated and a 3′-hydroxyl (OH) end to generate a phosphodiester linkage, employing either ATP or ...
[27]
Recent advances in DNA assembly technologies - PMC
Similar to SLIC, the Gibson assembly method (Gibson et al., 2009) utilizes T5 exonuclease to chew back the 5′ ends to generate single-stranded complementary ...
[28]
[PDF] Gibson Assembly Cloning Guide, second edition
The Gibson Assembly® method is a cloning procedure that allows the cloning of two or more fragments without the need for restriction enzyme digestion or ...
[29]
The art of vector engineering: towards the construction of next ...
One of the first and most significant artificial vectors developed was the pBR322 (Bolivar et al., 1977) which was derived from ColE1. This vector, still ...
[30]
Why DNA Repl... | Learn Science at Scitable - Nature
Dec 22, 2011 · This part of the vector name stands for Bolivar and Rodriguez, two of the scientists who constructed the pBR322 cloning vector in 1977. They ...
[31]
Overview: Recombinant Viral Vectors as Neuroscience Tools - PMC
Apr 1, 2020 · Recombinant viral vectors are used for in vivo gene delivery, expanding the neurobiology toolbox for delivering tracers, sensors, and actuators ...
[32]
Critical Factors Affecting the Success of Cloning, Expression, and ...
E. coli is the most frequently used host for production of enzymes and other proteins by recombinant DNA technology. E. coli is preferable for its relative ...
[33]
From Cell Clones to Recombinant Protein Product Heterogeneity in ...
Feb 4, 2025 · Chinese hamster ovary (CHO) cells are commonly used to produce recombinant therapeutic proteins (RTPs). The yield of RTPs in CHO cells has ...
[34]
Plasmids 101: Transformation, Transduction, Bacterial Conjugation ...
Jun 25, 2019 · Electroporation on the other hand uses electrical pulses to create transient pores in the cell membrane that genetic material can pass through.
[35]
Sequence and characterization of shuttle vectors for molecular ... - NIH
Feb 19, 2021 · Shuttle vectors allow for the manipulation of DNA in a system that is easier to work in (such as in Escherichia coli), which can then be ...Missing: strategies | Show results with:strategies
[36]
Generation of a Stable Plasmid for In Vitro and In Vivo Studies ... - NIH
LAC-p01 was genetically manipulated into an Escherichia coli-S. aureus shuttle vector that remained stable for at least 100 generations without antibiotic ...
[37]
https://www.neb.com/en-us/applications/protein-expression/protein-expression-in-e-coli/t7-expression
[38]
Regulating the T7 RNA polymerase expression in E. coli BL21 (DE3 ...
Sep 26, 2021 · BL21 (DE3) carries an inducible T7 RNA polymerase-dependent pET expression system that allows for the simple manipulation and tuning of protein ...
[39]
Codon Optimization: Understanding the Basics | IDT
Mar 31, 2025 · Codon optimization involves strategically modifying the nucleotide sequence of a gene to replace rare or less-favored codons with more ...
[40]
Codon Optimization for Increased Protein Expression | GenScript
There is little doubt that advances in codon optimization have the potential to significantly improve recombinant protein production, synthetic biology, and ...
[41]
https://www.cusabio.com/c-21182.html
[42]
Preparative Purification of Recombinant Proteins: Current Status ...
In this study, 90.2% purity along with 90% recovery was achieved and antigen binding activity was preserved in the product. The running time was reduced to one- ...
[43]
Challenges and opportunities in the purification of recombinant ...
The purification of recombinant proteins by affinity chromatography is one of the most efficient strategies due to the high recovery yields and purity achieved.
[44]
Cell-Free Protein Synthesis Explained | IDT
Minimal contamination: Since cell-free systems lack living cells, there is no risk of contamination by endotoxins or other cellular debris, simplifying ...Missing: 2020s | Show results with:2020s
[45]
https://www.cosmobiousa.com/blog/why-cell-free-protein-expression-can-be-better-than-cell-based-systems
[46]
Stability of recombinant DNA and its effects on fitness - PubMed
The stability of recombinant DNA is influenced by the fidelity of its genetic transmission and by its effects on fitness of the engineered organism.Missing: long- term
[47]
Methods for measuring the evolutionary stability of engineered ...
Aug 23, 2021 · Here, we provide a method for jointly estimating the mutation rate of transgene loss and the strength of selection favoring these transgene-free ...
[48]
The sound of silence: Transgene silencing in mammalian cell ...
Dec 21, 2022 · Transgene silencing, defined as the loss of expression over time, persists as an obstacle for engineering primary cells and stem cells with transgenic cargos.
[49]
The Use of Chromatin Insulators to Improve the Expression ... - NIH
Nevertheless, the overwhelming evidence indicates that chromatin insulators can provide one means of reducing silencing chromosomal position effects on ...
[50]
Massively parallel characterization of insulator activity across the ...
Sep 27, 2024 · In theory, flanking transgenes with insulators protects them from position effects, but in practice, efforts to insulate transgenes meet ...
[51]
What is the difference between a recombinant protein and a native ...
May 10, 2017 · Consistency: typically, the yields obtained for recombinant antigens are significantly larger than those produced by native strains.
[52]
Comparative Immunogenicity of the Recombinant Receptor-Binding ...
Here, we describe the production of a recombinant RBD protein using prokaryotic (pRBD) and mammalian (mRBD) expression systems, and compare the immunogenicity ...
[53]
Summary statement of the Asilomar conference on ... - PNAS
The conference reviewed recombinant DNA research, agreed that no methodology is risk-free, and that containment should match the risk. Most work requires more ...
[54]
NIH Guidelines for Research Involving Recombinant or Synthetic ...
For research involving plants, four biosafety levels (BL1-P through BL4-P) are described in Appendix L, Physical and Biological Containment for Recombinant ...
[55]
High-risk human-caused pathogen exposure events from 1975-2016
Aug 4, 2021 · This paper reports on a dataset of 71 incidents involving either accidental or purposeful exposure to, or infection by, a highly infectious pathogenic agent.Missing: verified ecological
[56]
The Long Legacy of Recombinant DNA Hazard Debates for the ...
Mar 7, 2025 · On June 4, 1982, a technician at Biogen's Cambridge, Massachusetts laboratory poured five gallons of E. coli bacteria genetically engineered ...Missing: ecological | Show results with:ecological
[57]
Recombinant ASF Live Attenuated Virus Strains as Experimental ...
The recombinant virus lacking this gene, ASFV-G-∆I177L, had a drastic decrease in virulence compared to its parental virus strain. Animals receiving up to ...
[58]
A Comparative Analysis of Parental and Attenuated Strains of the ...
Jun 13, 2024 · This research provides an initial insight into the molecular basis of IBV attenuation and is expected to facilitate the development of new vaccines.
[59]
Science and History of GMOs and Other Food Modification Processes
Mar 5, 2024 · 1992: FDA policy states that foods from GMO plants must meet the same requirements, including the same safety standards, as foods derived from ...Missing: data recombinant
[60]
Human Health Effects of Genetically Engineered Crops - NCBI - NIH
In this chapter, the committee examines the evidence that substantiates or negates specific hypotheses and claims about the health risks and benefits ...<|separator|>
[61]
Effects of DNA Size on Transformation and Recombination ... - NIH
Recombination efficiency depends on homologous sequence length. We observed maximum recombination efficiency of a naturally transformed plasmid into the X.Missing: drop | Show results with:drop
[62]
Room temperature electrocompetent bacterial cells improve DNA ...
Apr 20, 2016 · Here we present simple temperature shift based methods that improve DNA transformation and recombineering efficiency in E. coli and several other gram-negative ...
[63]
Cloning Insulin - Genentech
Apr 7, 2016 · In 1982, the FDA approved human insulin and it was on the market by 1983. Since then, millions of people have used the medicine, and it has ...
[64]
100 Years of Insulin - FDA
Jun 8, 2022 · On October 28, 1982, after only 5 months of review, the FDA approved Humulin, the first biosynthetic human insulin product and the first ...
[65]
Recombinant Human Insulins – Clinical Efficacy and Safety in ... - NIH
The purity and pharmaceutical quality of recombinant human insulin was demonstrated to be superior to animal and semisynthetic insulin and patients with ...
[66]
The complexities of insulin allergy: a case and approach - PMC - NIH
Jul 29, 2021 · The prevalence of insulin allergy has decreased since the introduction of human recombinant insulin preparations. Hypersensitivity reactions ...
[67]
Recombinant Human Insulin in Global Diabetes Management
Recombinant human insulin is a mainstay for diabetes therapy, providing global access, with clinical efficacy established over 35 years. It is available in ...
[68]
Global Insulin Market Size to Surpass USD 41.63 Billion by 2033
Feb 27, 2024 · The global insulin market size was valued at USD 28.33 billion in 2023 and is projected to surpass around USD 41.63 billion by 2033, ...
[69]
25th Anniversary of First Product Approval - Genentech
Oct 18, 2010 · On October 18, 1985, Genentech received approval from the US Food and Drug Administration (FDA) to market its first product, a growth hormone for children with ...
[70]
The Era of Cadaveric Pituitary Extracted Human Growth Hormone ...
The first patient treated with cadaveric pituitary GH (hGH) was reported in 1958. Subsequently, collection of cadaveric pituitaries started in many countries ...
[71]
The history, physiology and treatment safety of growth hormone
May 24, 2021 · This review discusses the history, physiology and safety of growth hormone treatment, with focus on the long-term risks of mortality, cardiovascular morbidity ...
[72]
Current and emerging factor VIII replacement products for ... - NIH
Aug 26, 2017 · In 2016, Octocog alfa (Kovaltry®), a full-length, unmodified rFVIII, was FDA-approved based on the LEOPOLD I, II, and Kids trials. It has the ...
[73]
Factors affecting the quality, safety and marketing approval of ... - NIH
Donor selection procedures are designed to identify and exclude donors at risk of being infected with viruses that can be transmitted by blood transfusion. In ...
[74]
Trastuzumab for HER2-Positive Metastatic Breast Cancer - NIH
It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant ...
[75]
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast ...
Oct 20, 2005 · One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
[76]
25 Years of Trastuzumab: A Legacy of Innovation
Oct 17, 2023 · In a phase III clinical trial, patients with HER2-positive metastatic breast cancer had a median progression-free survival of 18.5 months when ...
[77]
25 years of Herceptin: A groundbreaking advancement in breast ...
Oct 18, 2023 · Now, depending on the stage of the cancer at diagnosis, women with HER2-positive breast cancer have among the highest survival rates of all ...<|separator|>
[78]
Targeting HER2-positive breast cancer - PubMed Central
Nov 7, 2022 · The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2+ breast cancer.
[79]
[PDF] Package Insert - Recombivax HB - FDA
RECOMBIVAX HB® Hepatitis B Vaccine (Recombinant). Suspension for intramuscular injection. Initial U.S. Approval: 1986.
[80]
Hepatitis B vaccine development and implementation - PMC
Mar 18, 2020 · In 1986, the recombinant HB vaccine was approved by the USA Food and Drug Administration. Since then, the recombinant hepatitis B vaccine has ...
[81]
Chapter 10: Hepatitis B | Pink Book - CDC
May 9, 2024 · The first recombinant HepB vaccine, Recombivax HB, was licensed in the United States in 1986. A second recombinant vaccine, Engerix-B, was ...<|separator|>
[82]
The Protective Efficacy of Recombinant Hepatitis B Vaccine in ...
... study of recombinant vaccine efficacy. They were randomized into 2 groups, A (54 infants) and B ... rates were 7.4 and 1.8%, in Groups A and B, respectively.
[83]
Hepatitis B Vaccines - PMC - NIH
Sep 30, 2021 · In 2019, coverage of 3 doses of the hepatitis B vaccine reached 85% worldwide compared to around 30% in 2000. The effective implementation of ...
[84]
COVID-19 mRNA Vaccine Production
Aug 31, 2021 · Plasmids are used in mRNA vaccine production because they are easy to replicate (copy) and reliably contain the target gene sequence.
[85]
COMPARING vaccine manufacturing technologies recombinant ...
Sep 18, 2024 · Recombinant DNA technology involves the insertion of a gene encoding the pathogen or immunoglobulin sequence of choice into a cell factory ...
[86]
The contemporary immunoassays for HIV diagnosis - NIH
This brief overview is based on advances of HIV diagnosis while focusing on the latest HIV testing technologies including HIV-specific antigens.
[87]
Human Immunodeficiency Virus Diagnostic Testing: 30 Years of ...
Apr 4, 2016 · The second-generation HIV test added recombinant antigens, and the third-generation HIV tests included IgM detection, reducing the test- ...
[88]
Detection of Acute HIV Infection in Two Evaluations of a New ... - CDC
Jun 21, 2013 · Early HIV IAs used either viral lysate antigens (first generation) or synthetic peptides and recombinant antigens (second generation) and ...
[89]
[PDF] Package Insert - ZOLGENSMA - FDA
ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with ...
[90]
Recombinant Adeno-Associated Virus Gene Therapy in Light of ...
In May 2019, Zolegensma, a one-time treatment for spinal muscular atrophy in pediatric patients less than 2 years of age, became the second FDA approved AAV ...
[91]
Symptomatic Clinical Study Results | ZOLGENSMA®
Read the ZOLGENSMA® STR1VE trial results in symptomatic children with spinal muscular atrophy (SMA). See Safety & Full Prescribing Info.
[92]
Efficacy and safety of gene therapy with onasemnogene ... - NIH
Oct 7, 2024 · This study demonstrates the real-world outcomes of 343 children with SMA treated with OA at a maximum follow-up of 43 months (mean 13.8 ± 9.5), ...
[93]
Twenty-eight years of GM Food and feed without harm: why not ...
Mar 12, 2024 · There are no cases where post-market surveillance has uncovered harm to consumers or the environment including potential transfer of DNA from ...
[94]
Do foods made with GMOs pose special health risks?
May 2, 2022 · No evidence has validated that eating food with GMO ingredients is harmful. · Scientists continue to study foods made from genetically engineered ...
[95]
Pocket K No. 6: Bt Insect Resistant Technology - ISAAA
Significant reductions have also been reported in China and Argentina, where the use of Bt cotton resulted in a 60-70% reduction in pesticide use. Greater ...
[96]
Long-term impact of Bt cotton: An empirical evidence from North India
Aug 20, 2021 · A steep decline in pesticide (insecticide) usage, particularly on Helicoverpa armigera, from 71% in 2001 to 3% in 2011 was reported and this ...
[97]
[PDF] Roundup Ready® Crops Have Major Positive Impact on Tillage ...
Growers in all states in the study showed an increase in conservation tillage after adopting Roundup. Ready crops in the crop rotation (data not shown). The ...
[98]
[PDF] Agricultural Biotechnology Can Help Mitigate Climate Change
Boosting Carbon Sequestration. The adoption of herbicide-tolerant (HT) crops, such as Roundup Ready soybeans, sugarbeets and rapeseed, permit farm ers to ...
[99]
https://apps.fas.usda.gov/newgainapi/api/Report/DownloadReportByFileName?fileName=Philippines%20First%20in%20World%20to%20Approve%20Golden%20Rice%20for%20Propagation_Manila_Philippines_07-01-2021.pdf
[100]
From Golden Rice to Golden Diets: How to turn its recent approval ...
Following its approval in the Philippines in July 2021, provitamin A-rich “Golden Rice” is set to become the worlds' first commercialized genetically modified ...
[101]
Microbial enzymes: industrial progress in 21st century - PMC - NIH
Aug 19, 2016 · Enzyme mediated processes are rapidly gaining interest because of reduced process time, intake of low energy input, cost effective, nontoxic and ...
[102]
Chymosin - an overview | ScienceDirect Topics
The American pharmaceutical company Pfizer perfected the GM technique in which RNA coding for chymosin is removed from the abomasum, inserted, using recombinant ...
[103]
Application of Recombinant Calf Chymosin in Cheesemaking
This revolutionary breakthrough eliminates cheesemakers' historical dependency on scarce and costly supply of milk-fed calf stomachs that, until now, was the ...
[104]
Fermented Chymosin Market Size, Demand & Forecast 2025-2035
Jul 12, 2025 · The fermented chymosin market is projected to grow from USD 5.2 billion in 2025 to USD 7.8 billion by 2035, which shows a CAGR of 4.2%.
[105]
[PDF] Novozymes, Inc. DECREASE Final Technical Report - OSTI.gov
The fold-improvement for CTec3 over CZP00005 in kettle at the 80% conversion target is 1.89X, calculated from the CTec EL of 2.93 mg/g cellulose +glucose +xylan ...
[106]
[PDF] Review of Recent Pilot Scale Cellulosic Ethanol Demonstration
Jul 31, 2013 · – Cellulase cost reduced 20 fold. 2nd round of DOE grants started in 2008 (DSM, Genencor, Novozymes, Verenium). CBH1 from T. reesei. E1 from A ...
[107]
Industrial Enzymes Market Size, Share, Growth Drivers, and Forecast
The industrial enzymes market is projected to expand from USD 8.42 billion in 2025 to USD 12.01 billion by 2030, at a CAGR of 7.3% during the forecast period.
[108]
Techno-economic analysis of the industrial production of a low-cost ...
Mar 29, 2018 · Here, we present a conceptual design and techno-economic evaluation of the production of a low-cost industrial enzyme using recombinant E. coli.
[109]
1952: Genes are Made of DNA
Apr 23, 2013 · Hershey and Chase figured that the virus transferred genetic material into the bacterium to direct the production of more virus. They knew that ...
[110]
GENETIC EXCHANGE IN SALMONELLA - ASM Journals
The stability of the transduced cells was verified by tests of many daughter colonies by replica plating (Lederberg and Lederberg, 1952) to normal and ...
[111]
A Structure for Deoxyribose Nucleic Acid - Nature
The determination in 1953 of the structure of deoxyribonucleic acid (DNA), with its two entwined helices and paired organic bases, was a tour de force in ...
[112]
Highlights of the DNA cutters: a short history of the restriction enzymes
The first of these new enzymes, HindII, was discovered in Hamilton ('Ham') Smith's laboratory at Johns Hopkins Medical School in 1970 (29). This was ...
[113]
DNA Ligase - an overview | ScienceDirect Topics
In 1967, DNA ligase was discovered independently by the Gellert, Lehman, Richardson, and Hurwitz Institute. Since its discovery, DNA ligase has become an ...
[114]
Circular SV40 DNA Molecules Containing Lambda Phage ... - PNAS
We have developed methods for covalently joining duplex DNA molecules to one another and have used these techniques to construct circular dimers of SV40 DNA.
[115]
1972: First Recombinant DNA
Apr 26, 2013 · The first production of recombinant DNA molecules, using restriction enzymes, occurred in the early 1970s. Recombinant DNA technology involves ...
[116]
Paul Berg: Recombinant DNA trailblazer - PMC - NIH
Nov 13, 2023 · SV40 is a DNA tumor virus, known to endow some host cells with properties of tumor cells; and E. coli, the planned host for the recombinant SV ...
[117]
Construction of Biologically Functional Bacterial Plasmids In Vitro
Newly constructed plasmids that are inserted into Escherichia coli by transformation are shown to be biologically functional replicons that possess genetic ...
[118]
The dawn of recombinant DNA | Nature Reviews Genetics
Oct 15, 2007 · In 1972, he made a hybrid molecule in vitro by inserting λ phage sequences into SV40. These reports immediately raised concerns, as E. coli, ...
[119]
Asilomar Conference (1975) | Embryo Project Encyclopedia
Jul 9, 2024 · The purpose was to discuss how to manage the risk of researchers unintentionally creating harmful or deadly pathogens through rDNA research. The ...
[120]
Taking responsibility: Asilomar and its legacy - Science
Jan 30, 2025 · In February 1975, leading molecular biologists gathered at the Asilomar conference center on the California coast to evaluate risks of the ...
[121]
1976: First Genetic Engineering Company
Apr 26, 2013 · In 1977, the company produced the first human protein in a bacterium. The San Francisco Bay area company isolated the genes for human insulin ...
[122]
Proof of Concept - Genentech
Apr 7, 2016 · When Bob Swanson and Herb Boyer founded Genentech in 1976, their goal was audacious: to create a business based on manipulating the genes of microorganisms.
[123]
Diamond v. Chakrabarty | 447 U.S. 303 (1980)
Diamond v. Chakrabarty: Patent protection is available for a micro-organism that is artificially constructed rather than naturally occurring.Missing: recombinant DNA
[124]
Diamond v. Chakrabarty | Case Brief for Law Students | Casebriefs
Diamond v. Chakrabarty Case Brief - Rule of Law: A live, man-made microorganism is a non-naturally occurring composition and therefore may be patented.Missing: decision | Show results with:decision
[125]
First Recombinant Insulin Marks 36th Year of DNA Technology
Nov 2, 2018 · In October 1982, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Humulin, the first human insulin for diabetes ...
[126]
Information for Epogen/Procrit (Epoetin alfa) - FDA
Apr 13, 2017 · Epogen/Procrit was approved on June 1, 1989 for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not ...
[127]
Amgen History
1989. On June 1, 1989, the FDA approves EPOGEN® (epoetin alfa). EPOGEN® is named Product of the Year, by Fortune magazine.
[128]
Mistakes Shorten Flavr Savr's Shelf Life
Apr 12, 2016 · Flavr Savr™ tomato, the first genetically modified (GM) food crop to be marketed commercially following FDA approval in 1994, ...
[129]
1994: FLAVR SAVR Tomato
May 6, 2013 · The FDA approved the sale of the first genetically modified food - the FLAVR SAVR tomato, deeming it as safe as conventionally-bred tomatoes.Missing: commercialization | Show results with:commercialization
[130]
Bt & Roundup Ready Crops - Wessels Living History Farm
Mycogen and Ciba Seeds (now Novartis Seeds) first introduced Bt corn hybrids in 1996. Farmers found out that the corn borers died after eating only a few bites ...
[131]
[PDF] Are Bt crops safe - US EPA
Beginning in the mid-1990s, crop plants expressing Bt genes were commercialized in the United States. Cry1Ab and Cry1F Bt corn are effective in controlling ...
[132]
[PDF] w5243.pdf - National Bureau of Economic Research
The incumbent firms were generally slow to adopt biotechnology, but as a group made great strides in the late 1980s in increasing their share of all commercial ...
[133]
A Programmable Dual-RNA–Guided DNA Endonuclease ... - Science
Jun 28, 2012 · Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA- ...
[134]
Development and Applications of CRISPR-Cas9 for Genome ...
In this Review, we describe the development and applications of Cas9 for a variety of research or translational applications while highlighting challenges as ...
[135]
Design and synthesis of a minimal bacterial genome - Science
JCVI-syn3. 0 is a working approximation of a minimal cellular genome, a compromise between small genome size and a workable growth rate for an experimental ...Missing: details | Show results with:details
[136]
JCVI-syn3.0 – A synthetic genome stripped bare! - PMC - NIH
Apr 25, 2016 · A minimal genome of 375 essential genes; significantly more than the theorized minimum, yet less than that found in nature, providing scope for the design and ...
[137]
Recombinant DNA Technology Market Size & Report | 2033
The global recombinant DNA technology market reached a value of USD 796.2 Billion in 2024 and grow at a CAGR of 3.9% to reach USD 1143.4 Billion by 2033.
[138]
Expedited Programs for Regenerative Medicine Therapies for ... - FDA
Sep 25, 2025 · FDA refers to such designation as “regenerative medicine advanced therapy” (RMAT) designation (see section III. C of this document).Missing: recombinant | Show results with:recombinant
[139]
Asilomar and recombinant DNA - NobelPrize.org
Aug 26, 2004 · This unique conference marked the beginning of an exceptional era for science and for the public discussion of science policy.
[140]
'The Andromeda Strain': An Interview with Luis Campos
Aug 12, 2025 · Asilomar happens in 1975. How did The Andromeda Strain seep into these recombinant DNA discussions and debates? Was it fully in the zeitgeist?
[141]
The recombinant DNA controversy: twenty years later. - PNAS
The fear of "Andromeda strains" has disappeared. Just as the recombinant DNA techniques marked a para- digmatic shift in science, so could the approach to their.
[142]
National Institutes of Health (NIH) - Facebook
Sep 9, 2025 · Nearly 50 years ago, NIH established a landmark policy that allowed recombinant DNA research to responsibly flourish.Missing: incidents | Show results with:incidents
[143]
National Academy of Sciences report finds no food safety or human ...
May 17, 2016 · National Academy of Sciences report finds no food safety or human health impacts from genetically engineered crops.Missing: GMO biosafety
[144]
Academies of Science finds GMOs not harmful to human health
May 17, 2016 · Genetically engineered crops are safe for humans and animals to eat and have not caused increases in cancer, obesity, gastrointestinal illnesses, kidney ...Missing: findings biosafety
[145]
Horizontal gene transfer from transgenic plants to terrestrial bacteria
In this review we indicate why putative HGT from plants to terrestrial (soil and plant associated) bacteria has raised concern in biosafety evaluations.<|control11|><|separator|>
[146]
Biosafety and Ecological Assessment of Genetically Engineered and ...
Jul 5, 2023 · In summary, the papers collected in this Special Issue addressed some crucial aspects of the interaction of GE crops with organisms in the ...
[147]
https://agbiotech.ces.ncsu.edu/wp-content/uploads/2016/05/NAS-Genetically-Engineered-Crops-Full-Report.pdf
[148]
Playing God | Sojourners
Playing God. By Jeremy Rifkin · August 1980. When this article appeared, Jeremy ... With genetic engineering, and specifically with recombinant DNA technology, we ...
[149]
Playing God in Frankenstein's Footsteps: Synthetic Biology and the ...
Nov 29, 2009 · The recombinant-DNA debate in the 1970s already gave rise even then to a book entitled Playing God [29]. In recent decades this accusation has ...
[150]
Thinking the unthinkable: how did human germline genome editing ...
Jul 2, 2021 · ... objection that applying gene splicing technology to alter future generations was Playing God. Having debunked the religious objections, the ...
[151]
A NEW INSULIN GIVEN APPROVAL FOR USE IN U.S.
Oct 30, 1982 · Humulin was found to be safe and effective in tests involving about 400 patients in 12 medical centers in the United States, according to Dr.
[152]
Viewpoint: Human insulin saga: Anomalous, successful 40-year ...
Oct 27, 2022 · There were no systematic problems with treating “naive” patients (who had never received injections of insulin) or those who switched from ...
[153]
The untold story of the 'circle of trust' behind the world's first gene ...
Aug 1, 2019 · The prospect of this irrevocable genetic change is why, since the advent of CRISPR as a genome editor 5 years earlier, the editing of human ...
[154]
CRISPR'd babies: human germline genome editing in the 'He ...
The world was shocked in Nov. 25, 2018 by the revelation that He Jiankui had used clustered regularly interspaced short palindromic repeats ('CRISPR') to edit ...
[155]
Bioconservatism, Partiality, and the Human- Nature Objection ... - jstor
“Bioconservatives” in the human enhancement debate endorse the conservative claim that we should reject the use of biotechnologies that enhance natural human ...
[156]
40 Years Ago: Firm Wins Supreme Court Case That Helped Launch ...
Jun 16, 2020 · The case deals with patent rights an inventor, Dr. Ananda M. Chakrabarty, had sought for a genetically engineered microorganism that breaks down ...<|separator|>
[157]
[PDF] Patents and Cumulative Innovation: Causal Evidence from the Courts
These rents would be expected to (largely) disappear in a regime without patents and this would reduce, perhaps sharply, incentives to conduct such R&D.
[158]
Why is insulin so expensive and what can be done to control its cost?
We explore reasons for the high cost of insulin and recommend some clinical and policy interventions to improve insulin access and affordability.
[159]
Patents and regulatory exclusivities on FDA-approved insulin products
Nov 16, 2023 · High prices can lead to nonadherence and are often sustained by patents and regulatory exclusivities that limit competition on brand-name ...Missing: critiques | Show results with:critiques
[160]
How do patents affect research investments? - PMC
One way in which the disclosure function of the patent system could affect research investments is if, by making patenting less attractive to private inventors, ...
[161]
[PDF] Public R&D Investments and Private-sector Patenting
This paper makes progress on each of these issues to provide causal evidence on the returns to public investments in biomedical research.1 Our empirical setting ...
[162]
Golden Rice Licensing Arrangements
Breeding institutions in developing countries may obtain a licence to use Golden Rice from the Humanitarian Board.
[163]
Monsanto Waives Fees on Golden Rice | Science | AAAS
But the company now says it will forgo fees from those patents for golden rice destined for poor countries. The decision "saves having to negotiate" a special ...
[164]
[PDF] Golden Rice: A Case Study in Intellectual Property Management and ...
Mar 1, 2002 · Further, this paper examines Golden Rice, a genetically engineered rice strain that accumulates beta-carotene (i.e., pro-vitamin. A) in the ...
[165]
Golden Rice and Intellectual Property
Free access for those who need it · The Basics of the Licensing Agreement between Syngenta and the inventors of Golden Rice · The essence of the Sublicensing ...
[166]
[PDF] Golden Rice: A Product-Development Partnership in Agricultural ...
IP (intellectual property) constraints are often per- ceived as barriers to market entry, especially when it comes to developing countries. This case study ...
[167]
A Meta-Analysis of the Impacts of Genetically Modified Crops
The number of publications finally included in the meta-analysis is 147 (Table S1). Figure 1. Selection of studies for inclusion in the meta-analysis.Missing: consensus | Show results with:consensus
[168]
Genetically-Engineered Crops Past Experience and Future Prospects
This consensus report examines a range of questions and opinions about the economic, agronomic, health, safety, or other effects of genetically engineered ...Missing: biosafety | Show results with:biosafety
[169]
Cochrane review: Hepatitis B immunisation for newborn infants of ...
Apr 10, 2007 · Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported on adverse events. Authors' conclusions. Vaccine, ...
[170]
Do GMOs cause 'superweeds'? - Genetic Literacy Project
But there is a consensus among weed scientists that GMOs do not uniquely cause the development of hardier weeds; other non GMO crops have more serious weed ...
[171]
Scientists call for moratorium on genetically modified foods - PMC
... Research Institute in Aberdeen had found evidence of immune system changes and organ damage in rats fed on genetically modified potatoes. Dr Pusztai was ...
[172]
With 2000+ global studies affirming safety, GM foods among most ...
Oct 8, 2013 · ... analyzed 1783 studies about the safety and environmental impacts of GMO foods—a staggering number. The researchers couldn't find a single ...Missing: meta- | Show results with:meta-